Sanofi Buys 72,378 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) major shareholder Sanofi bought 72,378 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, August 25th. The stock was acquired at an average cost of $481.36 per share, with a total value of $34,839,874.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Sanofi also recently made the following trade(s):
- On Thursday, August 24th, Sanofi bought 166,415 shares of Regeneron Pharmaceuticals stock. The stock was acquired at an average cost of $480.93 per share, with a total value of $80,033,965.95.
- On Friday, June 2nd, Sanofi bought 136,050 shares of Regeneron Pharmaceuticals stock. The stock was acquired at an average cost of $478.17 per share, with a total value of $65,055,028.50.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 487.12 on Thursday. The company has a 50-day moving average price of $487.65 and a 200-day moving average price of $435.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The company has a market cap of $51.65 billion, a PE ratio of 48.87 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the business earned $2.82 earnings per share. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/sanofi-buys-72378-shares-of-regeneron-pharmaceuticals-inc-regn-stock/1532899.html.
Several equities analysts have recently issued reports on REGN shares. Canaccord Genuity raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from $375.00 to $484.00 in a report on Friday, May 5th. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Vetr downgraded Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price objective on the stock. in a research note on Monday, May 15th. Piper Jaffray Companies upped their price objective on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research note on Tuesday, June 20th. Finally, BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research note on Monday, May 15th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $495.59.
Several hedge funds have recently made changes to their positions in the stock. Korea Investment CORP raised its stake in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the period. Fieldpoint Private Securities LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at $130,000. Sterling Investment Advisors Ltd. increased its position in Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 28 shares in the last quarter. FNY Managed Accounts LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at $140,000. Finally, FNY Partners Fund LP increased its position in Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 67.96% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.